Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL.
Deng B, Pan J, Liu Z, Liu S, Chen Y, Qu X, Zhang Y, Lin Y, Zhang Y, Yu X, Zhang Z, Niu X, Luan R, Ma M, Li X, Liu T, Wu X, Niu H, Chang AH, Tong C.
Deng B, et al. Among authors: niu x, niu h.
Mol Ther Methods Clin Dev. 2021 Oct 27;23:633-643. doi: 10.1016/j.omtm.2021.10.006. eCollection 2021 Dec 10.
Mol Ther Methods Clin Dev. 2021.
PMID: 34901308
Free PMC article.